Septerna, Inc. (SEPN)
Automate Your Wheel Strategy on SEPN
With Tiblio's Option Bot, you can configure your own wheel strategy including SEPN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SEPN
- Rev/Share 0.0165
- Book/Share 9.1099
- PB 1.1548
- Debt/Equity 0.0625
- CurrentRatio 32.193
- ROIC -0.0927
- MktCap 468753316.0
- FreeCF/Share -1.6551
- PFCF -6.4457
- PE -16.6428
- Debt/Assets 0.0577
- DivYield 0
- ROE -0.167
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SEPN | Wells Fargo | Overweight | Equal Weight | -- | $14 | Feb. 18, 2025 |
News
Analysts Think These Stocks Could More Than Double in Value
Published: May 23, 2025 by: MarketBeat
Sentiment: Negative
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.
Read More
Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect?
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 151.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline and partnership essentially for free. NVO will cover R&D costs for four programs, extending SEPN's cash runway and reducing burn rate, while de-risking early-stage development.
Read More
ETFs to Capitalize on the Novo Nordisk-Septerna Deal
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.
Read More
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.
Read More
Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies
Published: May 14, 2025 by: Proactive Investors
Sentiment: Positive
Septerna (NASDAQ:SEPN) shares surged almost 50% after the announcement of an exclusive global collaboration and license deal with Novo Nordisk (NYSE:NVO) to develop oral small molecule medicines targeting obesity and other cardiometabolic diseases. The partnership brings together Septerna's expertise in G protein-coupled receptor (GPCR) drug discovery with Nono Nordisk's established obesity and metabolic disease therapies, which include the injectables Wegovy and Ozempic.
Read More
Wall Street Analysts Predict a 207.31% Upside in Septerna, Inc. (SEPN): Here's What You Should Know
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 207.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Published: March 31, 2025 by: Seeking Alpha
Sentiment: Positive
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.
Read More
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well-Capitalized with $420.8M Balance Sheet as of YE 2024 to Support Operating Runway into Early 2028 SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today provided a corporate overview complete with upcoming milestones and reported fourth quarter and full year 2024 …
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
Published: March 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Septerna, Inc ("Septerna" or the "Company") (NASDAQ:SEPN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
Published: March 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Septerna, Inc ("Septerna" or the "Company") (NASDAQ: SEPN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
Published: March 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Septerna, Inc ("Septerna" or the "Company") (NASDAQ:SEPN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
Published: March 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Septerna, Inc ("Septerna" or the "Company") (NASDAQ:SEPN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Shareholders to Reach Out
Published: March 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SEPN). Investors who purchased Septerna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SEPN.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
Published: March 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Septerna, Inc ("Septerna" or the "Company") (NASDAQ:SEPN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Shareholders to Learn More About the Investigation
Published: March 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SEPN). Investors who purchased Septerna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SEPN.
Read More
Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Published: March 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SEPN). Investors who purchased Septerna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SEPN.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Septerna, Inc. - SEPN
Published: March 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Septerna, Inc ("Septerna" or the "Company") (NASDAQ: SEPN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Septerna, Inc. (SEPN) And Encourages Investors to Connect
Published: February 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SEPN). Investors who purchased Septerna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SEPN.
Read More
Septerna to Present at TD Cowen 45th Annual Health Care Conference
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D.
Read More
Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Published: February 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SEPN). Investors who purchased Septerna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SEPN.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Investors to Inquire about Securities Investigation
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SEPN). Investors who purchased Septerna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SEPN.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Investors to Reach Out
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SEPN). Investors who purchased Septerna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SEPN.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Stockholders to Reach Out
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SEPN). Investors who purchased Septerna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SEPN.
Read More
Septerna halts Phase 1 hypoparathyroidism trial, shares plummet
Published: February 18, 2025 by: Proactive Investors
Sentiment: Negative
Septerna (NASDAQ:SEPN) shares tumbled more than 60% after the clinical-stage biotechnology firm announced it is halting its Phase 1 clinical trial of SEP-786 targeting hypoparathyroidism. The company said it chose to discontinue the trial due to the occurrence of elevated bilirubin levels in trial participants.
Read More
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative to SEP-786 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery, today announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers.
Read More
About Septerna, Inc. (SEPN)
- IPO Date 2024-10-25
- Website https://septerna.com
- Industry Biotechnology
- CEO Dr. Jeffrey T. Finer M.D., Ph.D.
- Employees 75